Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptimmune Therapeutics plc filings document material events for a U.K.-incorporated biopharmaceutical issuer whose American Depositary Shares represent ordinary shares. Recent Form 8-K disclosures cover ADS listing compliance, Nasdaq Capital Market status, financial-results releases, executive appointments and departures, severance arrangements, and changes to material agreements.
The company’s filings also record corporate actions tied to its cell therapy asset transactions, including the repayment of indebtedness under a loan and security agreement. Governance and capital-structure disclosures focus on ADS registration, ordinary-share representation, management responsibilities for financial reporting, and public-company compliance matters.
EcoR1 Capital, LLC, a 10% owner of Adaptimmune Therapeutics plc (ADAP), filed a Form 4 disclosing three consecutive open-market sales of American Depositary Shares (ADSs) between 28-30 Jul 2025.
- 28 Jul 2025: sold 5,655,290 ADSs (33,931,740 ordinary shares) at a $0.1125 weighted-average price.
- 29 Jul 2025: sold 447,910 ADSs (2,687,460 shares) at $0.1012.
- 30 Jul 2025: sold 4,572,223 ADSs (27,433,338 shares) at $0.1021.
The aggregate disposal totals 10,675,423 ADSs, equivalent to 64,052,538 ordinary shares. Post-transaction, EcoR1’s beneficial ownership stands at 16,728,647 ADSs (100,371,882 ordinary shares) held indirectly through its funds.
No derivative transactions were reported. The filing signals a sizable reduction in EcoR1’s stake, though the firm remains an insider owning more than 10% of ADAP’s equity.
Adaptimmune Therapeutics (ADAP) has agreed to sell its four autologous T-cell therapy programs—TECELRA, lete-cel, afami-cel and uza-cel—to US WorldMeds for $55 million cash at closing plus up to $30 million in regulatory and commercial milestones.
Proceeds will immediately repay the company’s outstanding Hercules Capital loan. US WorldMeds will assume selected liabilities, acquire manufacturing assets, licences and regulatory files, and offer jobs to roughly half of Adaptimmune’s staff. Adaptimmune will provide transition services through 30 June 2026.
Restructuring: Following the deal, Adaptimmune plans to cut its remaining workforce by ≈62 %, booking $7–8 million in severance costs (mainly Q3-25). Senior leaders—including the Chief Medical, Commercial, Scientific and Financial Officers—will depart in August 2025.
The transaction must close by 4 Aug 2025, subject to customary conditions and the absence of any material adverse effect.
- $5 M on FDA BLA acceptance for lete-cel
- $10 M on FDA approval for lete-cel
- Up to $5 M if TECELRA quarterly U.S. sales ≥$18 M
- $10 M if combined U.S. sales of TECELRA & lete-cel ≥$200 M